This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (106)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Neurology  • Alzheimer Disease  • Dementias  • Diagnosis  • Genetic Disorders  • Alert me on articles by topic

Jeffrey L. Cummings, MD; Greg Cole, PhD

JAMA. 2002;287:2335-2338.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Alzheimer disease (AD), the most common cause of dementia in the elderly, is a progressive neurodegenerative disorder that gradually robs the patient of cognitive function and eventually causes death. We review the epidemiology, clinical features, pathophysiology, and treatment of AD.

Incidence, Prevalence, and Economic Impact

Alzheimer disease accounts for 60% to 70% of cases of progressive cognitive impairment in elderly patients. The total prevalence of AD in the United States is estimated at 2.3 million (range, 1.09-4.8 million).¹ The prevalence of AD doubles every 5 years after the age of 60 increasing from a prevalence of 1% among those 60- to 64-years-old to up to 40% of those aged 85 years and older.² The disease is more common among women than men by a ratio of 1.2 to 1.5.³ The number of new cases per year is estimated at 360 000 equating to 980 new cases per day or . . . [Full Text of this Article]

Clinical Diagnosis

Pathology

Molecular Genetics and Pathogenesis

Treatment

Challenges

Author Affiliations: Department of Neurology (Drs Cummings and Cole), Department of Psychiatry and Biobehavioral Sciences (Dr Cummings), University of California, Los Angeles, School of Medicine, and Veterans Affairs Greater Los Angeles Health Care System (Dr Cole).

RELATED ARTICLE

May 8, 2002
JAMA. 2002;287(18):2437-2438.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dementia of the Alzheimer Type
Jalbert et al.
Epidemiol Rev 2008;30:15-34.
ABSTRACT | FULL TEXT  

Occupational risk factors in Alzheimer's disease: a review assessing the quality of published epidemiological studies
Santibanez et al.
Occup. Environ. Med. 2007;64:723-732.
ABSTRACT | FULL TEXT  

Does This Patient Have Dementia?
Holsinger et al.
JAMA 2007;297:2391-2404.
ABSTRACT | FULL TEXT  

References
APPI Online CME 2007;2007:2-2.
FULL TEXT  

Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial
Peskind et al.
AJGP 2006;14:704-715.
ABSTRACT | FULL TEXT  

Effect of Subchronic Treatment of Memantine, Galantamine, and Nicotine in the Brain of Tg2576 (APPswe) Transgenic Mice
Unger et al.
J. Pharmacol. Exp. Ther. 2006;317:30-36.
ABSTRACT | FULL TEXT  

Can We Escape Stroke and Alzheimer Disease?
Kurth and Logroscino
Stroke 2006;37:279-280.
FULL TEXT  

Physical Activity, APOE Genotype, and Dementia Risk: Findings from the Cardiovascular Health Cognition Study
Podewils et al.
Am J Epidemiol 2005;161:639-651.
ABSTRACT | FULL TEXT  

Dementia with Lewy Bodies: Molecular Pathogenesis and Implications for Classification
Cummings
J Geriatr Psychiatry Neurol 2004;17:112-119.
ABSTRACT  

Marked Increase in Alzheimer's Disease Identified in Medicare Claims Records Between 1991 and 1999
Taylor et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2004;59:M762-M766.
ABSTRACT | FULL TEXT  

Alzheimer disease risk associated with APOE4 is modified by STH gene polymorphism
Seripa et al.
Neurology 2004;62:1631-1633.
ABSTRACT | FULL TEXT  

Executive Dysfunction in Alzheimer Disease
Swanberg et al.
Arch Neurol 2004;61:556-560.
ABSTRACT | FULL TEXT  

Hippocampal Neuron Loss Exceeds Amyloid Plaque Load in a Transgenic Mouse Model of Alzheimer's Disease
Schmitz et al.
Am. J. Pathol. 2004;164:1495-1502.
ABSTRACT | FULL TEXT  

Meta-Analysis of the Association of the Cathepsin D Ala224Val Gene Polymorphism with the Risk of Alzheimer's Disease: A HuGE Gene-Disease Association Review
Ntais et al.
Am J Epidemiol 2004;159:527-536.
ABSTRACT | FULL TEXT  

Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial
Tariot et al.
JAMA 2004;291:317-324.
ABSTRACT | FULL TEXT  

Labeled cortical mantle distance maps of the cingulate quantify differences between dementia of the Alzheimer type and healthy aging
Miller et al.
Proc. Natl. Acad. Sci. USA 2003;100:15172-15177.
ABSTRACT | FULL TEXT  

Genetic background regulates {beta}-amyloid precursor protein processing and {beta}-amyloid deposition in the mouse
Lehman et al.
Hum Mol Genet 2003;12:2949-2956.
ABSTRACT | FULL TEXT  

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer's Disease
Krishnan et al.
Am. J. Psychiatry 2003;160:2003-2011.
ABSTRACT | FULL TEXT  

{beta}-Amyloid Peptide Activates Non-{alpha}7 Nicotinic Acetylcholine Receptors in Rat Basal Forebrain Neurons
Fu and Jhamandas
J. Neurophysiol. 2003;90:3130-3136.
ABSTRACT | FULL TEXT  

Frameshifted {beta}-Amyloid Precursor Protein (APP+1) Is a Secretory Protein, and the Level of APP+1 in Cerebrospinal Fluid Is Linked to Alzheimer Pathology
Hol et al.
J. Biol. Chem. 2003;278:39637-39643.
ABSTRACT | FULL TEXT  

Cerebrospinal fluid shunting for Alzheimer's disease?
Bennett and McDermott
Neurology 2002;59:1126-1127.
FULL TEXT